These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153 [TBL] [Abstract][Full Text] [Related]
15. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Pfeifer MA; Schumer MP; Gelber DA Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505 [TBL] [Abstract][Full Text] [Related]
16. Structural-functional interactions in the therapeutic response of diabetic neuropathy. Sima AA; Greene DA Diabet Med; 1993; 10 Suppl 2():33S-34S. PubMed ID: 8334838 [No Abstract] [Full Text] [Related]
17. Medical therapy in the prevention of cataract. Brown NA; Bron AJ Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085 [TBL] [Abstract][Full Text] [Related]
18. Effects of aldose reductase inhibitors on the progression of nerve damage. Greene DA; Sima AA Diabet Med; 1993; 10 Suppl 2():31S-32S. PubMed ID: 8334837 [No Abstract] [Full Text] [Related]
19. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Gabbay KH Curr Diab Rep; 2004 Dec; 4(6):405-8. PubMed ID: 15539002 [TBL] [Abstract][Full Text] [Related]